Effectiveness of WeChat-based interventions for glycemic control in patients with diabetes mellitus: A systematic review and meta-analysis.
WeChat-based interventions may significantly reduce HbA1c in diabetes patients, but the clinical relevance of this finding requires further investigation.
Where it sits
this study against the rest of the humanin corpusSummary and findings
This systematic review and meta-analysis evaluated WeChat-based interventions for glycemic control in patients with diabetes mellitus, including type 1, type 2, and gestational diabetes. The primary outcome measured was the mean difference in glycated hemoglobin (HbA1c). The analysis included 1,742 participants across seven studies, revealing a statistically significant reduction in HbA1c.
Abstract
<h4>Background</h4>WeChat, China's dominant mobile super-application with over one billion active users, offers a uniquely accessible and scalable digital health intervention. Despite a growing body of primary research, no meta-analysis has yet synthesized evidence across all three major diabetes subtypes type 1 (T1DM), type 2 (T2DM), and gestational diabetes mellitus (GDM) for WeChat-based programs.<h4>Methods</h4>This systematic review and meta-analysis was conducted in accordance with PRISMA 2020 guidelines. Three major databases (PubMed, ClinicalTrials.gov, Cochrane CENTRAL) were searched from inception to 23 April 2026. Eligible studies were selected examining WeChat-based interventions versus usual care in patients with T1DM, T2DM, or GDM, reporting glycemic or cardiometabolic outcomes. The primary outcome was the mean difference (MD) in glycated haemoglobin (HbA1c).<h4>Results</h4>7 studies encompassing 1,742 participants were included (six RCTs, one quasi-experimental study). WeChat-based interventions produced a statistically significant pooled reduction in HbA1c (MD -1.10%, 95% CI -1.78 to -0.42; I<sup>2</sup> = 85%; four studies). Fasting blood glucose showed a non-significant directional reduction (MD -0.36 mmol/L, 95% CI -0.76 to 0.03). Two-hour postprandial glucose was significantly reduced (MD -0.21 mmol/L). Diastolic blood pressure was significantly lower in intervention groups (MD -1.59), while systolic blood pressure did not reach significance.<h4>Conclusion</h4>WeChat-based digital health interventions significantly reduce HbA1c and confer additional benefits on glycemic and cardiometabolic parameters across T1DM, T2DM, and GDM populations. These platforms represent a scalable, low-cost adjunct to conventional diabetes care, especially in Chinese primary health settings. Larger, methodologically rigorous trials with longer follow-up and cost-effectiveness analyses are warranted.
Background
This paper addresses the effectiveness of WeChat-based interventions for glycemic control in diabetes mellitus, a growing area of interest due to the increasing prevalence of diabetes. Prior research has indicated potential benefits of digital health interventions, but no comprehensive meta-analysis has synthesized evidence across the three major diabetes subtypes. The study's findings could inform future digital health strategies in diabetes management.
Methods
This systematic review and meta-analysis followed PRISMA 2020 guidelines, searching three major databases up to April 23, 2026. Eligible studies included those comparing WeChat-based interventions to usual care in patients with type 1, type 2, or gestational diabetes, focusing on glycemic and cardiometabolic outcomes. The primary outcome was the mean difference in glycated hemoglobin (HbA1c).
Results
The primary endpoint showed a pooled reduction in HbA1c of MD -1.10% (95% CI -1.78 to -0.42; I²=85%) across seven studies with 1,742 participants. Additionally, fasting blood glucose decreased by MD -0.36 mmol/L (95% CI -0.76 to 0.03), which was not statistically significant. Two-hour postprandial glucose was significantly reduced by MD -0.21 mmol/L, and diastolic blood pressure was significantly lower by MD -1.59.
Interpretation
The findings suggest that WeChat-based interventions can lead to statistically significant reductions in HbA1c, though the clinical significance of a -1.10% reduction may vary among individuals. The high heterogeneity (I²=85%) indicates variability in study results, which may limit the generalizability of the findings. The study's reliance on a limited number of trials and potential confounding factors necessitates caution in interpreting these results for clinical practice.
Key findings
- MD -1.10% HbA1c (95% CI -1.78 to -0.42), I²=85%; n=1,742.
- MD -0.36 mmol/L fasting blood glucose (95% CI -0.76 to 0.03), not significant.
- MD -0.21 mmol/L two-hour postprandial glucose, significant.
- MD -1.59 diastolic blood pressure, significant.
- Systolic blood pressure did not reach significance.
Limitations
- High heterogeneity (I²=85%) among studies.
- Small number of included studies (n=7).
- Potential confounding factors not fully addressed.
- Short follow-up duration.
- Lack of cost-effectiveness analysis.